(PharmaNewsWire.Com, November 21, 2017 ) Microbiome is genetic material of all microbes such as bacteria, virus, fungi and protozoa that live on and inside the human body. Every part of the body has different types of microbes. For instance, about a third bacteria in the gut are Bacteriodes species, whereas Streptococcus species are dominant about oral health. Microbiomes plays significant role in human health and disease conditions.
Increase in evidence about the direct relationship of microbiome in treating life style diseases, autoimmune diseases such as Crohn’s, inflammatory bowel disease (IBS) conditions are fuelling the growth of the market. Currently, very few drugs are available in the market to treat these disease conditions. Furthermore, microbiome therapeutics are safer than conventional treatments as they are already present in human body. Microbiome therapeutics didn’t possess any side-effects unlike conventional drugs these factors will have positive impact on the growth of the market. However, lack of substantial clinical evidence about the microbiome benefits on human health and regulatory barriers might hamper the growth of the market over the forecast period.
Microbiome Therapeutics Market has been segmented based on Product Type, and Disease Indication
Based on the product type, Microbiome Therapeutics Market has been segmented into the following: • Probiotics • Prebiotics • Synbiotics (Combination of Prebiotics and Probiotics)
Based on Disease Indication, Microbiome Therapeutics Market has been segmented into the following: • Digestive related disorders o o Crohn’s disease o o Inflammatory Bowel Disease (IBD) o o Irritable Bowel Syndrome (IBS) o o Others • Metabolic Disorders o o Obesity o o Diabetes o o Others • Respiratory Infections • Cancer • Immune System • Oral Diseases • Skin Infections • Others
Microbiome Therapeutics Market is still nascent stage, very products in the market are currently approved to treat various therapeutic conditions. Start-ups are very active in the microbiome therapeutics market in terms of product launches, research and development activities. However, bigger players in microbiome therapeutics market are focused to provide funding, collaborating and acquiring with smaller players to promote the research activities. Furthermore, Venture Capitalists and Government Organisations are actively involved in funding and encouraging the research activities. Launch of microbiome therapeutics products in the market expected to fuel the demand of the market over the forecast. For instance, in May 2014, Pfizer entered an agreement with Second Genome to conduct research on obesity and metabolic disorders. In April 2016, company also raised US$ 42.6 Mn in Series B funding led by Pfizer Venture Investments and Roche Venture Fund. The funding amount will be used to conduct clinical investigation on SGM-109, a small molecule inhibitor of microbiome mediated target to address inflammation and pain conditions in ulcerative colitis. In February 2016, Synlogic raised US$ 40 Mn in Series-B from OrbisMed Healthcare Fund Management to expand its research programs on inflammatory bowel disease conditions and to develop therapeutics for inborn errors of metabolism of Urea Cycle Disorder and Phenylketonuria conditions.
Geographically market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Europe accounted for larger share in terms of research and development followed by North America. Active involvement of government organisation owing to encourage the research on microbiome in European countries. For instance, MetaGenoPolis (MGP) program that was financed by French Initiative “Investissements d’Avenir” to understand the human microbiome impact on human health. In June 2014, MyNewGut project received funding from European Union, to develop dietary interventions that have impact on controlling obesity, diabetes, and cardiovascular disease conditions. In Asia-Pacific region, research on microbiome therapeutics is also actively carried out by research institutes through government funding programs. In 2010, Korean Microbiome Diversity Using Korean Twin Cohort Project was funded by National Research Foundation of Korea. The aim of the project is to identify target microbiome and genes that are associated with human diseases.
Global Microbiome Therapeutics Market dominated by key players such as Johnson & Johnson, Pfizer Inc., AB biotics, Enterome, Seres Therapeutics, Vedanta Biosciences, Eligo Bioscience, 4D Pharma plc, Synlogic, TargEDys, Second Genome, LNC research & development, Takeda Pharmaceutical Company Ltd, PROBI, and Ritter Pharmaceuticals.
About Precision Business Insights Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs. Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.
Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights
Contact to Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX Email: sales@precisionbusinessinsights.com Toll Free (US): +1-866-598-1553 Website @ https://www.precisionbusinessinsights.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
